Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: Evaluation of national cancer institute of canada clinical trials group CO.17 Trial

N. Mittmann^*, H.-J. Au, D. Tu, C.J. O'Callaghan, P.K. Isogai, C.S. Karapetis, J.R. Zalcberg, W.K. Evans, Malcolm Moore, J. Siddiqui, Brian Findlay, B. Colwell, J. Simes, P. Gibbs, M. Links, N.C. Tebbutt, D.J. Jonker

^*Corresponding author for this work